Lomedeucitinib (BMS-986322) is act by targeting receptor tyrosine protein kinase (TYK2). Lomedeucitinib can be used for the research of plaque psoriasis.
References:
[1]. Lomedeucitinib by Bristol-Myers Squibb for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval.
















